Ma'mon M. Hatmal

Dr. Ma'mon M. Hatmal

Hashemite University, Zarqa, Jordan
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MHMa'mon M. Hatmal
Ma'mon M. Hatmal
Mohammad A. I. Al-HatamlehMohammad A. I. Al-Hatamleh
Mohammad A. I. Al-Hatamleh
AOAmin Olaimat
Amin Olaimat
MHMalik Hatmal
Malik Hatmal
DADina Alhaj-Qasem
Dina Alhaj-Qasem
RMRohimah Mohamud
Rohimah Mohamud
Background: Since the coronavirus disease 2019 (COVID-19) was declared a pandemic, there was no doubt that vaccination is the ideal protocol to tackle it. Within a year, a few COVID-19 vaccines have been developed and authorized. This unparalleled initiative in developing vaccines created many uncertainties looming around the efficacy and safety of these vaccines. This study aimed to assess the side effects and perceptions following COVID-19 vaccination in Jordan. Methods: A cross-sectional study was conducted by distributing an online survey targeted toward Jordan inhabitants who received any COVID-19 vaccines. Data were statistically analyzed and certain machine learning (ML) tools, including multilayer perceptron (MLP), eXtreme gradient boosting (XGBoost), random forest (RF), and K-star were used to predict the severity of side effects. Results: A total of 2213 participants were involved in the study after receiving Sinopharm, AstraZeneca, Pfizer-BioNTech, and other vaccines (38.2%, 31%, 27.3%, and 3.5%, respectively). Generally, most of the post-vaccination side effects were common and non-life-threatening (e.g., fatigue, chills, dizziness, fever, headache, joint pain, and myalgia). Only 10% of participants suffered from severe side effects; while 39% and 21% of participants had moderate and mild side effects, respectively. Despite the substantial variations between these vaccines in the presence and severity of side effects, the statistical analysis indicated that these vaccines might provide the same protection against COVID-19 infection. Finally, around 52.9% of participants suffered before vaccination from vaccine hesitancy and anxiety; while after vaccination, 95.5% of participants have advised others to get vaccinated, 80% felt more reassured, and 67% believed that COVID-19 vaccines are safe in the long term. Furthermore, based on the type of vaccine, demographic data, and side effects, the RF, XGBoost, and MLP gave both high accuracies (0.80, 0.79, and 0.70, respectively) and Cohen’s kappa values (0.71, 0.70, and 0.56, respectively). Conclusions: The present study confirmed that the authorized COVID-19 vaccines are safe and getting vaccinated makes people more reassured. Most of the post-vaccination side effects are mild to moderate, which are signs that body’s immune system is building protection. ML can also be used to predict the severity of side effects based on the input data; predicted severe cases may require more medical attention or even hospitalization.

8 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
MHMa'mon M. Hatmal
Ma'mon M. Hatmal
WAWalhan Alshaer
Walhan Alshaer
Mohammad A. I. Al-HatamlehMohammad A. I. Al-Hatamleh
Mohammad A. I. Al-Hatamleh
MHMalik Hatmal
Malik Hatmal
othman smadiothman smadi
othman smadi
Magdalena PlebanskiMagdalena Plebanski
Magdalena Plebanski
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has recently emerged in China and caused a disease called coronavirus disease 2019 (COVID-19). The virus quickly spread around the world, causing a sustained global outbreak. Although SARS-CoV-2, and other coronaviruses, SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV) are highly similar genetically and at the protein production level, there are significant differences between them. Research has shown that the structural spike (S) protein plays an important role in the evolution and transmission of SARS-CoV-2. So far, studies have shown that various genes encoding primarily for elements of S protein undergo frequent mutation. We have performed an in-depth review of the literature covering the structural and mutational aspects of S protein in the context of SARS-CoV-2, and compared them with those of SARS-CoV and MERS-CoV. Our analytical approach consisted in an initial genome and transcriptome analysis, followed by primary, secondary and tertiary protein structure analysis. Additionally, we investigated the potential effects of these differences on the S protein binding and interactions to angiotensin-converting enzyme 2 (ACE2), and we established, after extensive analysis of previous research articles, that SARS-CoV-2 and SARS-CoV use different ends/regions in S protein receptor-binding motif (RBM) and different types of interactions for their chief binding with ACE2. These differences may have significant implications on pathogenesis, entry and ability to infect intermediate hosts for these coronaviruses. This review comprehensively addresses in detail the variations in S protein, its receptor-binding characteristics and detailed structural interactions, the process of cleavage involved in priming, as well as other differences between coronaviruses.

4 November 2022 in Emerging Microbes & Infections
Verified
Journal Article
Open access
MHMa'mon M. Hatmal
Ma'mon M. Hatmal
MAMohammad A. I. Al-Hatamleh
Mohammad A. I. Al-Hatamleh
AOAmin N. Olaimat
Amin N. Olaimat
SASuhana Ahmad
Suhana Ahmad
Hanan HasanHanan Hasan
Hanan Hasan
RMRohimah Mohamud
Rohimah Mohamud
The current outbreak of monkeypox (MPX) infection has emerged as a global matter of concern in the last few months. MPX is a zoonosis caused by the MPX virus (MPXV), which is one of the Orthopoxvirus species. Thus, it is similar to smallpox caused by the variola virus, and smallpox vaccines and drugs have been shown to be protective against MPX. Although MPX is not a new disease and is rarely fatal, the current multi-country MPX outbreak is unusual because it is occurring in countries that are not endemic for MPXV. In this work, we reviewed the extensive literature available on MPXV to summarize the available data on the major biological, clinical and epidemiological aspects of the virus and the important scientific findings. This review may be helpful in raising awareness of MPXV transmission, symptoms and signs, prevention and protective measures. It may also be of interest as a basis for performance of studies to further understand MPXV, with the goal of combating the current outbreak and boosting healthcare services and hygiene practices. Trial registration: ClinicalTrials.gov identifier: NCT02977715.. Trial registration: ClinicalTrials.gov identifier: NCT03745131.. Trial registration: ClinicalTrials.gov identifier: NCT00728689.. Trial registration: ClinicalTrials.gov identifier: NCT02080767..

29 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Mohammad A. I. Al-HatamlehMohammad A. I. Al-Hatamleh
Mohammad A. I. Al-Hatamleh
MHMa'mon M. Hatmal
Ma'mon M. Hatmal
KSKamran Sattar
Kamran Sattar
SASuhana Ahmad
Suhana Ahmad
ZMZulkifli Mustafa
Zulkifli Mustafa
RMRohimah Mohamud
Rohimah Mohamud
The new coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has recently put the world under stress, resulting in a global pandemic. Currently, there are no approved treatments or vaccines, and this severe respiratory illness has cost many lives. Despite the established antimicrobial and immune-boosting potency described for honey, to date there is still a lack of evidence about its potential role amid COVID-19 outbreak. Based on the previously explored antiviral effects and phytochemical components of honey, we review here evidence for its role as a potentially effective natural product against COVID-19. Although some bioactive compounds in honey have shown potential antiviral effects (i.e., methylglyoxal, chrysin, caffeic acid, galangin and hesperidinin) or enhancing antiviral immune responses (i.e., levan and ascorbic acid), the mechanisms of action for these compounds are still ambiguous. To the best of our knowledge, this is the first work exclusively summarizing all these bioactive compounds with their probable mechanisms of action as antiviral agents, specifically against SARS-CoV-2.

24 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MHMa'mon M. Hatmal
Ma'mon M. Hatmal
Mohammad A. I. Al-HatamlehMohammad A. I. Al-Hatamleh
Mohammad A. I. Al-Hatamleh
AOAmin Olaimat
Amin Olaimat
WAWalhan Alshaer
Walhan Alshaer
Hanan HasanHanan Hasan
Hanan Hasan
RMRohimah Mohamud
Rohimah Mohamud
Infants who are exclusively breastfed in the first six months of age receive adequate nutrients, achieving optimal immune protection and growth. In addition to the known nutritional components of human breast milk (HBM), i.e., water, carbohydrates, fats and proteins, it is also a rich source of microRNAs, which impact epigenetic mechanisms. This comprehensive work presents an up-to-date overview of the immunomodulatory constituents of HBM, highlighting its content of circulating microRNAs. The epigenetic effects of HBM are discussed, especially those regulated by miRNAs. HBM contains more than 1400 microRNAs. The majority of these microRNAs originate from the lactating gland and are based on the remodeling of cells in the gland during breastfeeding. These miRNAs can affect epigenetic patterns by several mechanisms, including DNA methylation, histone modifications and RNA regulation, which could ultimately result in alterations in gene expressions. Therefore, the unique microRNA profile of HBM, including exosomal microRNAs, is implicated in the regulation of the genes responsible for a variety of immunological and physiological functions, such as FTO, INS, IGF1, NRF2, GLUT1 and FOXP3 genes. Hence, studying the HBM miRNA composition is important for improving the nutritional approaches for pregnancy and infant’s early life and preventing diseases that could occur in the future. Interestingly, the composition of miRNAs in HBM is affected by multiple factors, including diet, environmental and genetic factors.

25 July 2011 in Biopolymers
Verified
Journal Article
Closed access
PDF file
MHMa'mon M. Hatmal
Ma'mon M. Hatmal
YLYiyu Li
Yiyu Li
BHBalachandra G. Hegde
Balachandra G. Hegde
PHPrabhavati B. Hegde
Prabhavati B. Hegde
CJChristine C. Jao
Christine C. Jao
IHIan Haworth
Ian Haworth